Francesco Maria Lavino
Algemeen Directeur bij F2G Ltd.
Actieve functies van Francesco Maria Lavino
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Directeur/Bestuurslid | 12-04-2021 | - |
| Algemeen Directeur | 12-04-2021 | - | |
| F2g Inc. | Directeur/Bestuurslid | - | - |
| President | - | - |
Loopbaan van Francesco Maria Lavino
Eerdere bekende functies van Francesco Maria Lavino
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | 01-09-2015 | 01-07-2017 |
| CUBIST PHARMACEUTICALS INC | Verkoop & Marketing | 01-12-2013 | 01-09-2015 |
| MERCK & CO., INC. | Directeur/Bestuurslid | 01-01-2011 | 01-11-2013 |
| NABRIVA THERAPEUTICS PLC | Corporate Officer/Principal | 10-07-2017 | - |
Opleiding van Francesco Maria Lavino
| Università degli Studi di Napoli Federico II | Undergraduate Degree |
| SDA Bocconi School of Management | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Italië | 3 |
| Ierland | 2 |
Operationeel
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Sales & Marketing | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NABRIVA THERAPEUTICS PLC | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
| F2g Inc. |
